Bicara Therapeutics Inc. Common Stock (BCAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has a cash flow conversion efficiency ratio of -0.073x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.25 Million) by net assets ($402.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bicara Therapeutics Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Bicara Therapeutics Inc. Common Stock for a breakdown of total debt and financial obligations.
Bicara Therapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aerospace Cf
SHG:600855
|
-0.017x |
|
Guangdong Macro Co Ltd
SHE:000533
|
0.065x |
|
Jiangsu Jiuding New Material Co Ltd
SHE:002201
|
0.069x |
|
Carlsberg Brewery Malaysia Bhd
KLSE:2836
|
0.097x |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
0.055x |
|
WEIBO CORP. A
F:2WB
|
N/A |
|
Csg Smart Science&Technology Co Ltd
SHE:300222
|
0.084x |
|
Novocure Ltd
NASDAQ:NVCR
|
0.060x |
Annual Cash Flow Conversion Efficiency for Bicara Therapeutics Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Bicara Therapeutics Inc. Common Stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Bicara Therapeutics Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $491.88 Million | $-74.75 Million | -0.152x | +27.22% |
| 2023-12-31 | $218.51 Million | $-45.63 Million | -0.209x | -111.25% |
| 2022-12-31 | $-17.28 Million | $-32.08 Million | 1.856x | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumor… Read more